Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 11/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.67 |
| ▸ | EPAS1 | Q99814 | 5/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | GMNN | O75496 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13237887 | 0.88 | PDE5A (0.53) | PDE5AHIF1AEPAS1KDM4ENPC1 | |
| SCHEMBL7500320 | 0.84 | PDE5A (0.46) | PDE5AHIF1AEPAS1KDM4ENPC1 | |
| SCHEMBL13618712 | 0.83 | PDE5A (0.66) | PDE5AHIF1AEPAS1KDM4ENPC1 | |
| SCHEMBL5103308 | 0.81 | PDE5A (0.48) | PDE5AHIF1AEPAS1KDM4ENPC1 | |
| SCHEMBL187837 | 0.81 | PDE5A (1.00) | PDE5AHIF1AEPAS1KDM4ENPC1 | |
| SCHEMBL29352550 | 0.81 | PDE5A (1.00) | PDE5AHIF1AEPAS1KDM4ENPC1 | |
| SCHEMBL2950333 | 0.80 | PDE5A (0.46) | PDE5AHIF1AEPAS1KDM4ENPC1 | |
| SCHEMBL7094721 | 0.77 | ADORA1 (0.50) | PDE5AALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL1310633 | 0.77 | PDE5A (0.67) | PDE5AHIF1AEPAS1KDM4ENPC1 | |
| SCHEMBL5564430 | 0.77 | PDE5A (0.71) | PDE5AHIF1AEPAS1KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754751-B2 | Preferential inhibition of release of pro-inflammatory cytokines | YUNG SHIN PHARMACEUTICAL IND. CO., LTD. (TW) | 2010-07-13 | — | — | US | disclosed |
| US-7754751-B2 | Preferential inhibition of release of pro-inflammatory cytokines | YUNG SHIN PHARMACEUTICAL IND. CO., LTD. (TW) | 2010-07-13 | — | — | US | disclosed |
| US-7754751-B2 | Preferential inhibition of release of pro-inflammatory cytokines | YUNG SHIN PHARMACEUTICAL IND. CO., LTD. (TW) | 2010-07-13 | — | — | US | disclosed |
| US-7378532-B2 | Fused pyrazolyl compound | YUNG SHIN PHARMACEUTICAL IND. CO., LTD. (TW) | 2008-05-27 | — | — | US | disclosed |
| EP-1586572-A1 | Fused pyrazolyls as anti-cancer drugs | Yung Shin Pharm. Ind. Co. Ltd. (TW) | 2005-10-19 | — | — | EP | disclosed |
| US-20050215613-A1 | Preferential inhibition of release of pro-inflammatory cytokines | YUNG SHIN PHARMACEUTICAL IND. CO., LTD. (TW) | 2005-09-29 | — | — | US | disclosed |
| US-20050215612-A1 | Novel fused pyrazolyl compound | YUNG SHIN PHARMACEUTICAL IND. CO., LTD. (TW) | 2005-09-29 | — | — | US | disclosed |
| EP-1576954-A1 | Preferential inhibition of release of pro-inflammatory cytokines | Yung Shin Pharm. Ind. Co. Ltd. (TW) | 2005-09-21 | — | — | EP | disclosed |
| US-6387942-B2 | PYRAZOLYL COMPOUND; ANTICOAGULANTS, ANTIPROLIFERATIVE AGENT | YUNG SHIN PHARMACEUTICAL IND. CO. LTD (TW) | 2002-05-14 | — | — | US | disclosed |
| US-20020004518-A1 | Method of treating disorders related to protease-activated receptors-induced cell activation | YUNG SHIN PHARMACEUTICAL IND. CO., LTD. (TW) | 2002-01-10 | — | — | US | disclosed |
| EP-1166785-A1 | Use of pyrazole derivatives for inhibiting thrombin-induced platelet aggregation | Yung Shin Pharmeutical Ind. Co., Ltd. (TW) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215613-A1 | Preferential inhibition of release of pro-inflammatory cytokines | IL1RN, IL1R1, NFRKB | PDE5A 2439/4885HIF1A 1404/4885EPAS1 3199/4885 |
| US-20050215612-A1 | Novel fused pyrazolyl compound | AR, ARL1, NR5A2 | PDE5A 2742/4885HIF1A 3218/4885EPAS1 2213/4885 |
| US-20020004518-A1 | Method of treating disorders related to protease-activated receptors-induced cell activation | F2R, HPN, F2RL1 | PDE5A 3372/4885HIF1A 2934/4885EPAS1 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.